Literature DB >> 29663308

Insights into the effects of the endocannabinoid system in cancer: a review.

Ana Isabel Fraguas-Sánchez1, Cristina Martín-Sabroso1, Ana Isabel Torres-Suárez1,2.   

Abstract

In the last few decades, the endocannabinoid system has attracted a great deal of interest in terms of its applications to clinical medicine. In particular, its applications in cancer probably represent one of the therapeutic areas with most promise. On the one hand, expression of the endocannabinoid system is altered in numerous types of tumours, compared to healthy tissue, and this aberrant expression has been related to cancer prognosis and disease outcome, suggesting a role of this system in tumour growth and progression that depends on cancer type. On the other hand, cannabinoids exert an anticancer activity by inhibiting the proliferation, migration and/or invasion of cancer cells and also tumour angiogenesis. However, some cannabinoids, at lower concentrations, may increase tumour proliferation, inducing cancer growth. Enough data has been provided to consider the endocannabinoid system as a new therapeutic target in cancer, although further studies to fully establish the effect of cannabinoids on tumour progression are still needed.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29663308      PMCID: PMC6003657          DOI: 10.1111/bph.14331

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  130 in total

1.  Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.

Authors:  Simona Pisanti; Paola Picardi; Lucia Prota; Maria Chiara Proto; Chiara Laezza; Paul G McGuire; Lucia Morbidelli; Patrizia Gazzerro; Marina Ziche; Arup Das; Maurizio Bifulco
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

Review 2.  The role of monoacylglycerol lipase (MAGL) in the cancer progress.

Authors:  Hong Qin; Zhi-hua Ruan
Journal:  Cell Biochem Biophys       Date:  2014-09       Impact factor: 2.194

3.  The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

Authors:  Anna Maria Malfitano; Chiara Laezza; Mario Galgani; Giuseppe Matarese; Alba D'Alessandro; Patrizia Gazzerro; Maurizio Bifulco
Journal:  Pharmacol Res       Date:  2011-11-22       Impact factor: 7.658

4.  Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.

Authors:  L X Zhu; S Sharma; M Stolina; B Gardner; M D Roth; D P Tashkin; S M Dubinett
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

5.  Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production.

Authors:  Murielle Mimeault; Nicole Pommery; Nicole Wattez; Christian Bailly; Jean-Pierre Hénichart
Journal:  Prostate       Date:  2003-06-15       Impact factor: 4.104

6.  Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors.

Authors:  Enrico Michelino Messalli; Flavio Grauso; Rossella Luise; Anna Angelini; Raffaele Rossiello
Journal:  Am J Obstet Gynecol       Date:  2014-04-08       Impact factor: 8.661

7.  Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism.

Authors:  Michael P Endsley; Nitin Aggarwal; Marilyn A Isbell; Craig E Wheelock; Bruce D Hammock; John R Falck; William B Campbell; Kasem Nithipatikom
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

8.  G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1.

Authors:  Carina Hasenoehrl; David Feuersinger; Eva M Sturm; Thomas Bärnthaler; Ellen Heitzer; Ricarda Graf; Magdalena Grill; Martin Pichler; Stephan Beck; Lee Butcher; Dominique Thomas; Nerea Ferreirós; Rufina Schuligoi; Caroline Schweiger; Johannes Haybaeck; Rudolf Schicho
Journal:  Int J Cancer       Date:  2017-09-21       Impact factor: 7.396

9.  Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival.

Authors:  Esther Martínez-Martínez; Irene Gómez; Paloma Martín; Antonio Sánchez; Laura Román; Eva Tejerina; Félix Bonilla; Antonio García Merino; Antonio García de Herreros; Mariano Provencio; Jose M García
Journal:  Oncoscience       Date:  2015-02-09

10.  Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.

Authors:  Mohamad Elbaz; Dinesh Ahirwar; Janani Ravi; Mohd W Nasser; Ramesh K Ganju
Journal:  Oncotarget       Date:  2017-05-02
View more
  25 in total

Review 1.  Insights into the effects of the endocannabinoid system in cancer: a review.

Authors:  Ana Isabel Fraguas-Sánchez; Cristina Martín-Sabroso; Ana Isabel Torres-Suárez
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

2.  The Endocannabinoid System in Caenorhabditis elegans.

Authors:  Rubén Estrada-Valencia; María Eduarda de Lima; Aline Colonnello; Edgar Rangel-López; Nariani Rocha Saraiva; Daiana Silva de Ávila; Michael Aschner; Abel Santamaría
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021-08-17       Impact factor: 5.545

3.  A fluorescent sensor for spatiotemporally resolved imaging of endocannabinoid dynamics in vivo.

Authors:  Ao Dong; Kaikai He; Barna Dudok; Jordan S Farrell; Wuqiang Guan; Daniel J Liput; Henry L Puhl; Ruyi Cai; Huan Wang; Jiali Duan; Eddy Albarran; Jun Ding; David M Lovinger; Bo Li; Ivan Soltesz; Yulong Li
Journal:  Nat Biotechnol       Date:  2021-11-11       Impact factor: 68.164

Review 4.  Medical Use of Cannabinoids.

Authors:  Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

5.  Transcription Profile and Pathway Analysis of the Endocannabinoid Receptor Inverse Agonist AM630 in the Core and Infiltrative Boundary of Human Glioblastoma Cells.

Authors:  Gareth Williams; David Chambers; Ruman Rahman; Francisco Molina-Holgado
Journal:  Molecules       Date:  2022-03-22       Impact factor: 4.411

6.  Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice.

Authors:  Silvia Marino; Daniëlle de Ridder; Ryan T Bishop; Nathalie Renema; Marco Ponzetti; Antonia Sophocleous; Mattia Capulli; Abdullah Aljeffery; Giovana Carrasco; Marianela Dalghi Gens; Asim Khogeer; Stuart H Ralston; Jürg Gertsch; Francois Lamoureux; Dominique Heymann; Nadia Rucci; Aymen I Idris
Journal:  EBioMedicine       Date:  2019-05-29       Impact factor: 8.143

Review 7.  Cannabis, the Endocannabinoid System and Immunity-the Journey from the Bedside to the Bench and Back.

Authors:  Osnat Almogi-Hazan; Reuven Or
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 8.  The Interplay between the Immune and the Endocannabinoid Systems in Cancer.

Authors:  Mariantonia Braile; Simone Marcella; Gianni Marone; Maria Rosaria Galdiero; Gilda Varricchi; Stefania Loffredo
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

Review 9.  Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.

Authors:  Natasha Irrera; Alessandra Bitto; Emanuela Sant'Antonio; Rita Lauro; Caterina Musolino; Alessandro Allegra
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

10.  Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis.

Authors:  Xue Shen; Hua Duan; Sha Wang; Lu Gan; Qian Xu; Jin-Jiao Li
Journal:  Biomed Res Int       Date:  2019-01-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.